Merck & Co's HPV vaccine protects older women
This article was originally published in Scrip
Executive Summary
Women aged 24-45 years who are not already infected with the human papillomavirus (HPV) types that cause most cervical cancers can benefit from Merck's Gardasil, according to Phase III trial results.